Pregabalin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Peripheral Neuropathic Pain (DPN)
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
Trial Timeline
Jan 1, 2007 → Jul 1, 2008
NCT ID
NCT00407511About Pregabalin
Pregabalin is a approved stage product being developed by Pfizer for Diabetic Peripheral Neuropathic Pain (DPN). The current trial status is completed. This product is registered under clinical trial identifier NCT00407511. Target conditions include Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV).
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Peripheral Neuropathic Pain (DPN) were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01773993 | Pre-clinical | Completed |
| NCT01603394 | Approved | Terminated |
| NCT01463306 | Phase 3 | Completed |
| NCT01298466 | Approved | Withdrawn |
| NCT01474772 | Phase 3 | Completed |
| NCT01397006 | Approved | Withdrawn |
| NCT01020526 | Approved | Completed |
| NCT01202227 | Phase 3 | Completed |
| NCT01226667 | Approved | Completed |
| NCT00819988 | Phase 3 | Completed |
| NCT00596466 | Phase 3 | Completed |
| NCT00553280 | Phase 3 | Completed |
| NCT01061697 | Approved | Completed |
| NCT00891397 | Pre-clinical | Terminated |
| NCT00448916 | Phase 3 | Completed |
| NCT00407797 | Approved | Terminated |
| NCT00424372 | Phase 3 | Completed |
| NCT00407511 | Approved | Completed |
| NCT00346034 | Phase 3 | Completed |
| NCT00843284 | Pre-clinical | Completed |
Competing Products
20 competing products in Diabetic Peripheral Neuropathic Pain (DPN)